ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma

Xu, Qingsheng; Huang, Kaiyuan; Meng, Xiangqi; Weng, Yuxiang; Zhang, Luyuan; Bu, Linghao; Zheng, Xiujue; Cai, Jinquan*; Zhan, Renya*; Chen, Qun*哈尔滨医科大学; 浙江大学; 1
Clinical Cancer Research2023-10-2DOI: 10.1158/1078-0432.CCR-23-0388
7阅读
引用收藏
分享

摘要

Purpose: Glioblastoma (GBM) is a highly vascularized tumor with few treatment options after disease recurrence. Here, we report the efficacy and safety of anlotinib hydrochloride plus temozolomide in patients with recurrent GBM.Patients and Methods: Patients with first definite postsurgical progression of histologically confirmed GBM preceded by standard radiotherapy and temozolomide chemotherapy were eligible for inclusion. All patients received temozolomide (150-200 mg/m2, orally, every day (QD) d1-5/4 wk) and anlotinib (10 mg, orally, QD, d1-14/3 wk) until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed 6-month progression-free survival (PFS) rate by the Response Assessment in Neuro-Oncology (RANO) criteria.Results: Twenty-one patients were enrolled between May 2020 and July 2021, with a median age of 55 (range 27-68) years old. According to the Response Assessment in Neuro-Oncology (RANO) criteria, tumor response occurred in 17 patients, of which 9 patients had a complete response, and the objective response rate was 81.0% [95% confidence interval (CI), 62.6-99.3]. The disease control rate was 95.2% (95% CI, 76.2-99.9), with three additional patients achieving a stable disease without tumor progression. The median PFS was 7.3 months (95% CI, 4.9-9.7), and the 6-month PFS rate was 61.9% (95% CI, 39.3-84.6). The median overall survival was 16.9 months (95% CI, 7.8-26.0). The most common adverse events were leukocytopenia (66.7%), thrombocytopenia (38.1%), and hypertriglyceridemia (38.1%). Five patients had nine grade 3 adverse events, with a 23.8% incidence rate. Two patients discontinued therapy due to ischemic stroke (grade 3) and wound dehiscence (grade 1), respectively. No grade 4 or treatment-related deaths occurred in this study.Conclusions: Anlotinib combined with temozolomide is efficacious and tolerated in patients with recurrent GBM.

学科与关键词

关键词
TYROSINE KINASE INHIBITORPHASE-II TRIALRESPONSE ASSESSMENTTUMOR VASCULATUREBEVACIZUMABTHERAPYACTIVATIONLOMUSTINEVEGFR2BETA
相关
加载中…
  • A phase II study of anlotinib combined with temozolomide in the treatment of patients with recurrent glioblastoma.
    Xu, Qingsheng; Chen, Qun; Zheng, Xiujue; Cai, Jinquan; Zhan, RenyaAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
  • Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway
    Xu, Peng; Wang, Handong*; Pan, Hao*; Chen, Jiakai; Deng, ChuleiCancer Chemotherapy and Pharmacology, 2022, 89(2): 183-196.被引 14
  • A Retrospective Study of Anlotinib Combined with Anti-PD-1 Inhibitors in the 2nd or Later-Line Treatment of Advanced Solid Tumors
    Li, Shu-hui; Li, Yi-Wen; Li, Ying-Jue; Liu, Lin-Bo; Zhang, Qun; Lu, Dan*International Journal of General Medicine, 2023, 16: 4485-4498.
查看全部 →

发表信息

论文状态
公开发表
期刊
Clinical Cancer Research
发表日期
2023-10-02
卷期
第 29 卷, 第 19 期
页码
3859-3866
DOI
10.1158/1078-0432.CCR-23-0388
语言
ENGLISH
成果收录
SCIE
资助标注
The publication costs of this article were defrayed in part by the payment of publication fees. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

作者

  • X

    Xu, Qingsheng (第一作者)

    1 · zhejiang univ

  • H

    Huang, Kaiyuan

    1 · zhejiang univ

查看全部 10 位作者收起作者
  • M

    Meng, Xiangqi

    2 · harbin med univ

  • W

    Weng, Yuxiang

    1 · zhejiang univ

  • Z

    Zhang, Luyuan

    1 · zhejiang univ

  • B

    Bu, Linghao

    1 · zhejiang univ

  • Z

    Zheng, Xiujue

    1 · zhejiang univ

  • C

    Cai, Jinquan (通讯)

    1 · zhejiang univ · 2 · harbin med univ

  • Z

    Zhan, Renya (通讯)

    1 · zhejiang univ

  • C

    Chen, Qun (通讯)

    1 · zhejiang univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417